

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Study Number:

C11054B-02

Study Sex:

Both

PWG Approval Date:

See web page for date of PWG Approval

Version:

v1.4.3

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Male: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	10	10	10	10	10
Censored	10	10	10	10	10
Early Deaths					
Survivors					
Number Animals Examined Microscopically	10				10
ALIMENTARY SYSTEM					
ESOPHAGUS	(10)	(0)	(0)	(0)	(10)
GALLBLADDER	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, CECUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, COLON	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, RECTUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, DUODENUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, ILEUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, JEJUNUM	(10)	(0)	(0)	(0)	(10)
LIVER	(10)	(0)	(0)	(0)	(10)
PANCREAS	(10)	(0)	(0)	(0)	(10)
SALIVARY GLAND	(10)	(0)	(0)	(0)	(10)
STOMACH, FORESTOMACH	(10)	(0)	(0)	(0)	(10)
STOMACH, GLANDULAR	(10)	(0)	(0)	(0)	(10)
CARDIOVASCULAR SYSTEM					
AORTA	(10)	(0)	(0)	(0)	(10)
HEART	(10)	(0)	(0)	(0)	(10)

Study Number: C11054B-02**Test Type:** TOX**Route:** Dosing in Water**Species/Strain:** Mouse/B6C3F1/N**PA02: Neoplastic Lesion Summary with Percent Incidence****Test Compound:** Sulfolane**CAS Number:** 126-33-0**Target Version:** Actions To Be Taken**Date Report Requested:** 11/14/2022**Time Report Requested:** 11:17:46**Lab:** Battelle with CRL

Male: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ENDOCRINE SYSTEM					
ADRENAL GLAND	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, CORTEX	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, MEDULLA	(10)	(0)	(0)	(0)	(10)
PARATHYROID GLAND	(10)	(0)	(0)	(0)	(8)
PITUITARY GLAND	(10)	(0)	(0)	(0)	(10)
THYROID GLAND	(10)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
EPIDIDYMIS	(10)	(0)	(0)	(0)	(10)
PREPUTIAL GLAND	(10)	(0)	(0)	(0)	(10)
PROSTATE	(10)	(0)	(0)	(0)	(10)
SEMINAL VESICLE	(10)	(0)	(0)	(0)	(10)
TESTIS	(10)	(0)	(0)	(0)	(10)
HEMATOLYMPHOID SYSTEM					
LYMPH NODE, MANDIBULAR	(10)	(0)	(0)	(0)	(10)
LYMPH NODE, MESENTERIC	(10)	(0)	(0)	(0)	(10)
SPLEEN	(10)	(0)	(0)	(0)	(10)
THYMUS	(10)	(0)	(0)	(0)	(10)
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(1)	(0)	(0)	(0)	(3)
SKIN	(10)	(0)	(0)	(0)	(10)
MUSCULOSKELETAL SYSTEM					
BONE, FEMUR	(10)	(0)	(0)	(0)	(10)
NERVOUS SYSTEM					
BRAIN	(10)	(0)	(0)	(0)	(10)

Male: Interim Animals					
Treatment Groups (mg/L)					
	0	30	100	300	1000
RESPIRATORY SYSTEM					
LUNG	(10)	(0)	(0)	(0)	(10)
NOSE	(10)	(0)	(0)	(0)	(10)
TRACHEA	(10)	(0)	(0)	(0)	(10)
SPECIAL SENSES SYSTEM					
EYE	(10)	(0)	(0)	(0)	(10)
HARDERIAN GLAND	(10)	(0)	(0)	(0)	(10)
URINARY SYSTEM					
KIDNEY	(10)	(0)	(0)	(0)	(10)
URINARY BLADDER	(10)	(0)	(0)	(0)	(10)
No Systemic Lesions					

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Tumor Summary Data for Male Interim Animals	Treatment Groups (mg/L)				
	0	30	100	300	1000
Total Animals with Primary Neoplasms	0	0	0	0	0
Total Primary Neoplasms	0	0	0	0	0
Total Animals with Benign Neoplasms	0	0	0	0	0
Total Benign Neoplasms	0	0	0	0	0
Total Animals with Malignant Neoplasms	0	0	0	0	0
Total Malignant Neoplasms	0	0	0	0	0
Total Animals with Metastatic Neoplasms	0	0	0	0	0
Total Metastatic Neoplasms	0	0	0	0	0
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	10	10	10	10	10
Censored	10	10	10	10	10
Early Deaths					
Survivors					
Number Animals Examined Microscopically	10		1		10
ALIMENTARY SYSTEM					
ESOPHAGUS	(10)	(0)	(0)	(0)	(10)
GALLBLADDER	(9)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, CECUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, COLON	(10)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, RECTUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, DUODENUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, ILEUM	(10)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, JEJUNUM	(10)	(0)	(0)	(0)	(10)
LIVER	(10)	(0)	(0)	(0)	(10)
PANCREAS	(10)	(0)	(0)	(0)	(10)
SALIVARY GLAND	(10)	(0)	(0)	(0)	(10)
STOMACH, FORESTOMACH	(10)	(0)	(0)	(0)	(10)
STOMACH, GLANDULAR	(10)	(0)	(0)	(0)	(10)
CARDIOVASCULAR SYSTEM					
AORTA	(10)	(0)	(0)	(0)	(10)
HEART	(10)	(0)	(0)	(0)	(10)

Study Number: C11054B-02**Test Type:** TOX**Route:** Dosing in Water**Species/Strain:** Mouse/B6C3F1/N**PA02: Neoplastic Lesion Summary with Percent Incidence****Test Compound:** Sulfolane**CAS Number:** 126-33-0**Target Version:** Actions To Be Taken**Date Report Requested:** 11/14/2022**Time Report Requested:** 11:17:46**Lab:** Battelle with CRL

Female: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ENDOCRINE SYSTEM					
ADRENAL GLAND	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, CORTEX	(10)	(0)	(0)	(0)	(10)
ADRENAL GLAND, MEDULLA	(10)	(0)	(0)	(0)	(10)
PARATHYROID GLAND	(10)	(0)	(0)	(0)	(9)
PITUITARY GLAND	(10)	(0)	(0)	(0)	(10)
THYROID GLAND	(10)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
CLITORAL GLAND	(10)	(0)	(0)	(0)	(10)
OVARY	(10)	(0)	(0)	(0)	(10)
UTERUS	(10)	(0)	(1)	(0)	(10)
STROMAL POLYP			1 (100%)		
UTERUS, CERVIX	(10)	(0)	(0)	(0)	(10)
VAGINA	(10)	(0)	(0)	(0)	(10)
HEMATOLYMPHOID SYSTEM					
LYMPH NODE, MANDIBULAR	(10)	(0)	(0)	(0)	(10)
LYMPH NODE, MESENTERIC	(10)	(0)	(0)	(0)	(10)
SPLEEN	(10)	(0)	(0)	(0)	(10)
THYMUS	(10)	(0)	(0)	(0)	(10)
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(10)	(0)	(0)	(0)	(10)
SKIN	(10)	(0)	(0)	(0)	(10)
MUSCULOSKELETAL SYSTEM					
BONE, FEMUR	(10)	(0)	(0)	(0)	(10)

Female: Interim Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
NERVOUS SYSTEM					
BRAIN	(10)	(0)	(0)	(0)	(10)
RESPIRATORY SYSTEM					
LUNG	(10)	(0)	(0)	(0)	(10)
NOSE	(10)	(0)	(0)	(0)	(10)
TRACHEA	(10)	(0)	(0)	(0)	(10)
SPECIAL SENSES SYSTEM					
EYE	(10)	(0)	(0)	(0)	(10)
HARDERIAN GLAND	(10)	(0)	(0)	(0)	(10)
URINARY SYSTEM					
KIDNEY	(10)	(0)	(0)	(0)	(10)
URINARY BLADDER	(10)	(0)	(0)	(0)	(10)
No Systemic Lesions					

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:17:46

Lab: Battelle with CRL

Tumor Summary Data for Female Interim Animals	Treatment Groups (mg/L)				
	0	30	100	300	1000
Total Animals with Primary Neoplasms	0	0	0	0	0
Total Primary Neoplasms	0	0	0	0	0
Total Animals with Benign Neoplasms	0	0	1	0	0
Total Benign Neoplasms	0	0	2	0	0
Total Animals with Malignant Neoplasms	0	0	0	0	0
Total Malignant Neoplasms	0	0	0	0	0
Total Animals with Metastatic Neoplasms	0	0	0	0	0
Total Metastatic Neoplasms	0	0	0	0	0
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	50	50	50	50	50
Censored					
Early Deaths					
Found Dead	11	10	10	14	13
Sacrificed, Moribund	5	12	5	4	8
Survivors					
Scheduled Sacrifice, Terminal	34	28	35	32	29
Number Animals Examined Microscopically	50	50	50	50	50

Study Number: C11054B-02**Test Type:** TOX**Route:** Dosing in Water**Species/Strain:** Mouse/B6C3F1/N**PA02: Neoplastic Lesion Summary with Percent Incidence****Test Compound:** Sulfolane**CAS Number:** 126-33-0**Target Version:** Actions To Be Taken**Date Report Requested:** 11/14/2022**Time Report Requested:** 11:17:46**Lab:** Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ALIMENTARY SYSTEM					
ESOPHAGUS	(50)	(50)	(50)	(49)	(50)
GALLBLADDER	(47)	(47)	(45)	(47)	(46)
INTESTINE, LARGE, CECUM	(50)	(50)	(50)	(50)	(50)
INTESTINE, LARGE, COLON	(50)	(50)	(49)	(50)	(49)
ADENOCARCINOMA		1 (2%)			
INTESTINE, LARGE, RECTUM	(50)	(50)	(50)	(50)	(49)
INTESTINE, SMALL, DUODENUM	(50)	(50)	(50)	(50)	(50)
ADENOMA	1 (2%)		1 (2%)		
LYMPHOMA; MALIGNANT				1 (2%)	
INTESTINE, SMALL, ILEUM	(49)	(50)	(49)	(50)	(50)
LEIOMYOSARCOMA					1 (2%)
INTESTINE, SMALL, JEJUNUM	(50)	(50)	(50)	(50)	(50)
ADENOCARCINOMA			1 (2%)	1 (2%)	
ADENOMA	2 (4%)	1 (2%)	2 (4%)		1 (2%)
HISTIOCYTIC SARCOMA			1 (2%)		
LEIOMYOMA			1 (2%)		
LEIOMYOSARCOMA; METASTATIC					1 (2%)
LIVER	(50)	(50)	(50)	(50)	(50)
HEMANGIOMA	2 (4%)	1 (2%)		1 (2%)	
HEMANGIOSARCOMA; MULTIPLE		1 (2%)	1 (2%)		1 (2%)
HEMANGIOSARCOMA	3 (6%)	4 (8%)	2 (4%)	2 (4%)	10 (20%)
HEPATOBLASTOMA; MULTIPLE		1 (2%)			2 (4%)
HEPATOBLASTOMA	7 (14%)	8 (16%)	7 (14%)	6 (12%)	4 (8%)
HEPATOCELLULAR ADENOMA; MULTIPLE	8 (16%)	1 (2%)	4 (8%)	7 (14%)	3 (6%)
HEPATOCELLULAR ADENOMA	14 (28%)	10 (20%)	11 (22%)	12 (24%)	12 (24%)
HEPATOCELLULAR CARCINOMA; MULTIPLE	5 (10%)	6 (12%)	5 (10%)		2 (4%)
HEPATOCELLULAR CARCINOMA	6 (12%)	9 (18%)	13 (26%)	13 (26%)	10 (20%)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
HEPATOCHOLANGIOCARCINOMA	1 (2%)	1 (2%)		1 (2%)	
HISTIOCYTIC SARCOMA		2 (4%)		1 (2%)	
LYMPHOMA; MALIGNANT				2 (4%)	
MESENTERY	(1)	(2)	(2)	(4)	(2)
HISTIOCYTIC SARCOMA		1 (50%)			
LEIOMYOSARCOMA; METASTATIC					1 (50%)
RHABDOMYOSARCOMA; METASTATIC	1 (100%)				1 (50%)
PANCREAS	(50)	(50)	(50)	(49)	(50)
HEPATOCHOLANGIOCARCINOMA; METASTATIC				1 (2%)	
HISTIOCYTIC SARCOMA			1 (2%)		
LYMPHOMA; MALIGNANT				1 (2%)	
RHABDOMYOSARCOMA; METASTATIC	1 (2%)				
SALIVARY GLAND	(50)	(50)	(50)	(50)	(50)
STOMACH, FORESTOMACH	(50)	(50)	(50)	(50)	(50)
LYMPHOMA; MALIGNANT				1 (2%)	
PAPILLOMA, SQUAMOUS				1 (2%)	
STOMACH, GLANDULAR	(50)	(50)	(50)	(50)	(50)
CARDIOVASCULAR SYSTEM					
AORTA	(50)	(50)	(50)	(50)	(50)
HEART	(50)	(50)	(50)	(50)	(50)
HEMANGIOSARCOMA				1 (2%)	
LYMPHOMA; MALIGNANT	1 (2%)				
RHABDOMYOSARCOMA; METASTATIC		1 (2%)			

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:17:46

Lab: Battelle with CRL

Male: Core Animals					
Treatment Groups (mg/L)					
	0	30	100	300	1000
ENDOCRINE SYSTEM					
ADRENAL GLAND	(47)	(50)	(50)	(50)	(50)
HIBERNOMA			1 (2%)		
ADRENAL GLAND, CORTEX	(47)	(50)	(50)	(50)	(50)
ADENOMA		1 (2%)			1 (2%)
ADRENAL GLAND, MEDULLA	(47)	(50)	(49)	(48)	(50)
ISLETS, PANCREATIC	(50)	(50)	(50)	(49)	(50)
PARATHYROID GLAND	(38)	(36)	(39)	(42)	(41)
PITUITARY GLAND	(43)	(47)	(47)	(47)	(47)
PARS DISTALIS; ADENOMA				2 (4%)	
THYROID GLAND	(50)	(50)	(49)	(49)	(50)
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
GENITAL SYSTEM					
COAGULATING GLAND	(0)	(0)	(1)	(0)	(0)
EPIDIDYMIS	(50)	(50)	(50)	(50)	(50)
HISTIOCYTIC SARCOMA		1 (2%)			
SPERM GRANULOMA	1 (2%)				1 (2%)
PENIS	(0)	(1)	(0)	(0)	(0)
PREPUTIAL GLAND	(50)	(49)	(50)	(49)	(49)
HISTIOCYTIC SARCOMA		1 (2%)			
PROSTATE	(50)	(50)	(50)	(50)	(50)
HEMANGIOMA			1 (2%)		
HISTIOCYTIC SARCOMA		1 (2%)			
SEMINAL VESICLE	(50)	(50)	(50)	(50)	(50)
HEPATOCHOLANGIOCARCINOMA; METASTATIC				1 (2%)	
TESTIS	(50)	(50)	(50)	(50)	(50)
HISTIOCYTIC SARCOMA		1 (2%)			
INTERSTITIAL CELL ADENOMA	1 (2%)		1 (2%)		

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:17:46

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
HEMATOLYMPHOID SYSTEM					
BONE MARROW	(50)	(50)	(50)	(50)	(50)
HEMANGIOSARCOMA		2 (4%)			1 (2%)
LYMPH NODE	(2)	(0)	(0)	(1)	(2)
RENAL; LYMPHOMA; MALIGNANT	1 (50%)			1 (100%)	2 (100%)
RENAL; RHABDOMYOSARCOMA; METASTATIC	1 (50%)				
LYMPH NODE, BRONCHIAL	(2)	(1)	(1)	(1)	(0)
ALVEOLAR/BRONCHIOLAR ADENOCARCINOMA; METASTATIC	1 (50%)				
HEPATOCELLULAR CARCINOMA; METASTATIC		1 (100%)	1 (100%)		
HEPATOCHOLANGIOCARCINOMA; METASTATIC				1 (100%)	
LYMPHOMA; MALIGNANT	1 (50%)				
LYMPH NODE, MANDIBULAR	(43)	(50)	(47)	(45)	(47)
HISTIOCYTIC SARCOMA		2 (4%)			
LYMPHOMA; MALIGNANT				1 (2%)	
LYMPH NODE, MEDIASTINAL	(0)	(0)	(0)	(2)	(0)
ALVEOLAR/BRONCHIOLAR ADENOCARCINOMA; METASTATIC				1 (50%)	
LYMPHOMA; MALIGNANT				1 (50%)	
LYMPH NODE, MESENTERIC	(50)	(48)	(47)	(49)	(47)
HEMANGIOMA			1 (2%)		
HEMANGIOSARCOMA			1 (2%)		
HISTIOCYTIC SARCOMA		2 (4%)	1 (2%)	1 (2%)	
LYMPHOMA; MALIGNANT	2 (4%)			3 (6%)	2 (4%)
RHABDOMYOSARCOMA; METASTATIC	2 (4%)				
SPLEEN	(49)	(50)	(50)	(50)	(50)
HEMANGIOMA					2 (4%)
HEMANGIOSARCOMA		5 (10%)	1 (2%)	1 (2%)	3 (6%)
HISTIOCYTIC SARCOMA		1 (2%)		1 (2%)	

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
LYMPHOMA; MALIGNANT	1 (2%)			2 (4%)	1 (2%)
THYMUS	(46)	(46)	(48)	(45)	(47)
HEMANGIOSARCOMA	1 (2%)				
HEPATOCELLULAR CARCINOMA; METASTATIC			1 (2%)		
THYMOMA; MALIGNANT				1 (2%)	
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(0)	(1)	(1)	(2)	(1)
SKIN	(50)	(50)	(50)	(50)	(50)
SEBACEOUS GLAND; EPIDERMIS; ADENOMA	1 (2%)				
HEMANGIOMA			1 (2%)		
HEMANGIOSARCOMA		2 (4%)		1 (2%)	1 (2%)
PAPILLOMA, SQUAMOUS		1 (2%)			1 (2%)
SCHWANNOMA; MALIGNANT				1 (2%)	1 (2%)
EPIDERMIS; TRICHOEPITHELIOMA					2 (4%)
TAIL	(0)	(0)	(0)	(0)	(1)
MUSCULOSKELETAL SYSTEM					
BONE, FEMUR	(50)	(50)	(50)	(50)	(50)
SKELETAL MUSCLE	(2)	(2)	(1)	(0)	(3)
HEMANGIOSARCOMA					2 (67%)
HEPATOCELLULAR CARCINOMA; METASTATIC			1 (100%)		
PERIORBITAL; RHABDOMYOSARCOMA		1 (50%)			
RHABDOMYOSARCOMA; MULTIPLE	1 (50%)				
RHABDOMYOSARCOMA	1 (50%)	1 (50%)			1 (33%)
NERVOUS SYSTEM					
BRAIN	(50)	(50)	(50)	(50)	(50)
LYMPHOMA; MALIGNANT				1 (2%)	

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Male: Core Animals					
Treatment Groups (mg/L)					
	0	30	100	300	1000
RESPIRATORY SYSTEM					
LUNG	(50)	(50)	(50)	(50)	(50)
ADENOCARCINOMA; METASTATIC	1 (2%)	1 (2%)			1 (2%)
ALVEOLAR/BRONCHIOLAR ADENOMA; MULTIPLE	1 (2%)	1 (2%)		3 (6%)	
ALVEOLAR/BRONCHIOLAR ADENOMA	8 (16%)	10 (20%)	11 (22%)	5 (10%)	9 (18%)
ALVEOLAR/BRONCHIOLAR CARCINOMA; MULTIPLE			1 (2%)	1 (2%)	
ALVEOLAR/BRONCHIOLAR CARCINOMA	1 (2%)	3 (6%)	3 (6%)	1 (2%)	3 (6%)
HEPATOBLASTOMA; METASTATIC	1 (2%)	2 (4%)	1 (2%)	1 (2%)	1 (2%)
HEPATOCELLULAR CARCINOMA; METASTATIC	4 (8%)	10 (20%)	12 (24%)	6 (12%)	8 (16%)
HEPATOCHOLANGIOCARCINOMA; METASTATIC	1 (2%)			1 (2%)	
HISTIOCYTIC SARCOMA		2 (4%)			
RHABDOMYOSARCOMA; METASTATIC	2 (4%)	1 (2%)			
NOSE	(50)	(50)	(50)	(50)	(50)
ADENOCARCINOMA; METASTATIC	1 (2%)				
POLYP	1 (2%)				
TRACHEA	(50)	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM					
EYE	(50)	(50)	(50)	(50)	(50)
HARDERIAN GLAND	(50)	(50)	(50)	(49)	(50)
ADENOCARCINOMA	1 (2%)		1 (2%)		1 (2%)
ADENOMA	5 (10%)	5 (10%)	3 (6%)	4 (8%)	4 (8%)
HISTIOCYTIC SARCOMA		1 (2%)		1 (2%)	
RHABDOMYOSARCOMA; METASTATIC		1 (2%)			
ZYMBALS GLAND	(0)	(0)	(1)	(0)	(0)
ADENOMA			1 (100%)		

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:17:46

Lab: Battelle with CRL

Male: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
URINARY SYSTEM					
KIDNEY	(50)	(50)	(50)	(49)	(50)
HEPATOCELLULAR CARCINOMA; METASTATIC			1 (2%)		
HISTIOCYTIC SARCOMA		1 (2%)			
LYMPHOMA; MALIGNANT				2 (4%)	
UROTHELIUM; PELVIS; PAPILLOMA					1 (2%)
URETER	(0)	(0)	(0)	(2)	(0)
URINARY BLADDER	(50)	(50)	(50)	(50)	(50)
SYSTEMIC LESIONS					
Multiple Organ(a)	(50)	(50)	(50)	(50)	(50)
HEMANGIOSARCOMA	3 (6%)	6 (12%)	4 (8%)	3 (6%)	12 (24%)
HISTIOCYTIC SARCOMA		2 (4%)	1 (2%)	1 (2%)	
LYMPHOMA	2 (4%)			3 (6%)	2 (4%)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Tumor Summary Data for Male Core Animals	Treatment Groups (mg/L)				
	0	30	100	300	1000
Total Animals with Primary Neoplasms	0	0	0	0	0
Total Primary Neoplasms	0	0	0	0	0
Total Animals with Benign Neoplasms	32	25	30	27	31
Total Benign Neoplasms	88	62	78	70	72
Total Animals with Malignant Neoplasms	22	31	28	29	29
Total Malignant Neoplasms	98	156	112	124	122
Total Animals with Metastatic Neoplasms	10	14	13	9	11
Total Metastatic Neoplasms	32	34	34	24	26
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
Disposition Summary					
Animals Initially In Study	50	50	50	50	50
Censored					
Early Deaths					
Found Dead	13	9	11	8	11
Sacrificed, Moribund	2	2	5	8	2
Survivors					
Scheduled Sacrifice, Terminal	35	39	34	34	37
Number Animals Examined Microscopically	50	50	50	50	50

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
ALIMENTARY SYSTEM					
ESOPHAGUS	(50)	(50)	(50)	(49)	(50)
RHABDOMYOSARCOMA					1 (2%)
GALLBLADDER	(49)	(49)	(46)	(47)	(47)
FIBROSARCOMA; METASTATIC	1 (2%)				
LYMPHOMA; MALIGNANT	1 (2%)				
INTESTINE, LARGE, CECUM	(50)	(50)	(50)	(49)	(50)
INTESTINE, LARGE, COLON	(50)	(50)	(50)	(50)	(50)
INTESTINE, LARGE, RECTUM	(49)	(50)	(49)	(48)	(50)
INTESTINE, SMALL, DUODENUM	(50)	(50)	(50)	(50)	(50)
INTESTINE, SMALL, ILEUM	(49)	(49)	(50)	(50)	(50)
INTESTINE, SMALL, JEJUNUM	(50)	(50)	(50)	(50)	(50)
ADENOCARCINOMA	2 (4%)		1 (2%)		
ADENOMA		1 (2%)		1 (2%)	
HISTIOCYTIC SARCOMA		1 (2%)			
LYMPHOMA; MALIGNANT	1 (2%)		2 (4%)		1 (2%)
LIVER	(50)	(50)	(50)	(50)	(50)
ADENOCARCINOMA; METASTATIC				1 (2%)	
CHOLANGIOCARCINOMA	1 (2%)				
FIBROSARCOMA; METASTATIC	1 (2%)				
HEMANGIOMA; MULTIPLE				1 (2%)	
HEMANGIOMA			1 (2%)	1 (2%)	
HEMANGIOSARCOMA; MULTIPLE			1 (2%)		
HEMANGIOSARCOMA		1 (2%)	1 (2%)	1 (2%)	1 (2%)
HEPATOBLASTOMA			1 (2%)		1 (2%)
HEPATOCELLULAR ADENOMA; MULTIPLE	4 (8%)			2 (4%)	5 (10%)
HEPATOCELLULAR ADENOMA	6 (12%)	5 (10%)	6 (12%)	9 (18%)	6 (12%)
HEPATOCELLULAR CARCINOMA; MULTIPLE			1 (2%)		

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
HEPATOCELLULAR CARCINOMA	2 (4%)	3 (6%)	4 (8%)	5 (10%)	8 (16%)
HEPATOCHOLANGIOCARCINOMA			1 (2%)		
HISTIOCYTIC SARCOMA		1 (2%)	1 (2%)	4 (8%)	2 (4%)
LYMPHOMA; MALIGNANT	3 (6%)	2 (4%)	2 (4%)		1 (2%)
OSTEOSARCOMA; METASTATIC			1 (2%)		
RHABDOMYOSARCOMA; METASTATIC		1 (2%)			
SCHWANNOMA; METASTATIC			1 (2%)		
MESENTERY	(8)	(2)	(7)	(13)	(9)
ADENOCARCINOMA; METASTATIC				1 (8%)	
FIBROSARCOMA; METASTATIC	1 (13%)				
FIBROSARCOMA					1 (11%)
HISTIOCYTIC SARCOMA				2 (15%)	
LIPOMA	1 (13%)				2 (22%)
LYMPHOMA; MALIGNANT				1 (8%)	
RHABDOMYOSARCOMA; METASTATIC	1 (13%)		1 (14%)		1 (11%)
PANCREAS	(50)	(50)	(49)	(50)	(50)
ADENOCARCINOMA				1 (2%)	
FIBROSARCOMA; METASTATIC	1 (2%)				
LYMPHOMA; MALIGNANT		1 (2%)	1 (2%)	2 (4%)	
RHABDOMYOSARCOMA; METASTATIC		1 (2%)			
SALIVARY GLAND	(50)	(49)	(50)	(50)	(49)
STOMACH, FORESTOMACH	(50)	(50)	(50)	(50)	(50)
PAPILLOMA, SQUAMOUS					1 (2%)
STOMACH, GLANDULAR	(50)	(50)	(50)	(50)	(50)
HISTIOCYTIC SARCOMA				1 (2%)	
NEUROENDOCRINE CELL TUMOR				1 (2%)	

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
CARDIOVASCULAR SYSTEM					
AORTA	(50)	(50)	(50)	(50)	(50)
HEART	(50)	(50)	(50)	(50)	(50)
FIBROSARCOMA; METASTATIC	1 (2%)				
HISTIOCYTIC SARCOMA				3 (6%)	
LYMPHOMA; MALIGNANT		2 (4%)			
SCHWANNOMA; METASTATIC			1 (2%)		
TUBULOSTROMAL CARCINOMA; METASTATIC	1 (2%)				
ENDOCRINE SYSTEM					
ADRENAL GLAND	(48)	(50)	(50)	(48)	(49)
ADENOCARCINOMA; METASTATIC		1 (2%)			
HISTIOCYTIC SARCOMA			1 (2%)		
ADRENAL GLAND, CORTEX	(48)	(50)	(50)	(48)	(49)
ADENOMA		1 (2%)			
LYMPHOMA; MALIGNANT		1 (2%)			
ADRENAL GLAND, MEDULLA	(48)	(50)	(50)	(47)	(49)
ISLETS, PANCREATIC	(50)	(50)	(50)	(50)	(50)
PARATHYROID GLAND	(35)	(32)	(38)	(31)	(24)
ADENOMA					1 (4%)
PITUITARY GLAND	(46)	(47)	(47)	(44)	(42)
PARS DISTALIS; ADENOMA	7 (15%)	4 (9%)	3 (6%)	2 (5%)	2 (5%)
PARS INTERMEDIA; ADENOMA	1 (2%)				
THYROID GLAND	(49)	(48)	(50)	(50)	(49)
FOLLICULAR CELL; ADENOMA	1 (2%)	1 (2%)	1 (2%)		
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
Treatment Groups (mg/L)					
	0	30	100	300	1000
GENITAL SYSTEM					
CLITORAL GLAND	(43)	(45)	(43)	(46)	(45)
OVARY	(48)	(46)	(47)	(48)	(49)
CYSTADENOMA	3 (6%)	2 (4%)	2 (4%)	1 (2%)	2 (4%)
HEMANGIOMA	2 (4%)			2 (4%)	2 (4%)
HEMANGIOSARCOMA					1 (2%)
HISTIOCYTIC SARCOMA				2 (4%)	1 (2%)
LUTEOMA; BENIGN		1 (2%)	1 (2%)		
LUTEOMA		1 (2%)			
OSTEOSARCOMA; METASTATIC					1 (2%)
THECOMA; BENIGN	1 (2%)				
TUBULOSTROMAL CARCINOMA	1 (2%)				
UTERUS	(50)	(50)	(50)	(50)	(50)
ADENOCARCINOMA				1 (2%)	1 (2%)
ENDOMETRIUM; ADENOMA	1 (2%)	1 (2%)			
GRANULAR CELL TUMOR; BENIGN, MULTIPLE			1 (2%)		
HEMANGIOMA			1 (2%)		
HISTIOCYTIC SARCOMA		1 (2%)		2 (4%)	
LYMPHOMA; MALIGNANT	1 (2%)			1 (2%)	
STROMAL POLYP		3 (6%)	1 (2%)	1 (2%)	1 (2%)
UTERUS, CERVIX	(50)	(50)	(50)	(50)	(50)
HISTIOCYTIC SARCOMA					1 (2%)
VAGINA	(50)	(50)	(50)	(50)	(50)
LYMPHOMA; MALIGNANT	1 (2%)				

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
HEMATOLYMPHOID SYSTEM					
BONE MARROW	(50)	(50)	(50)	(50)	(50)
HEMANGIOMA		1 (2%)			
HEMANGIOSARCOMA	1 (2%)				
LYMPHOMA; MALIGNANT	1 (2%)				
LYMPH NODE	(1)	(2)	(4)	(2)	(1)
LUMBAR; HISTIOCYTIC SARCOMA				1 (50%)	
RENAL; HISTIOCYTIC SARCOMA				1 (50%)	
ILLIAC; LYMPHOMA; MALIGNANT			3 (75%)		
LUMBAR; LYMPHOMA; MALIGNANT	1 (100%)	1 (50%)	3 (75%)		
PANCREATIC; LYMPHOMA; MALIGNANT			1 (25%)		
RENAL; LYMPHOMA; MALIGNANT			2 (50%)		
LYMPH NODE, AXILLARY	(2)	(0)	(1)	(0)	(0)
HEMANGIOMA	1 (50%)				
LYMPHOMA; MALIGNANT	1 (50%)		1 (100%)		
LYMPH NODE, BRONCHIAL	(1)	(1)	(3)	(1)	(2)
HISTIOCYTIC SARCOMA				1 (100%)	1 (50%)
LYMPHOMA; MALIGNANT	1 (100%)	1 (100%)	3 (100%)		1 (50%)
LYMPH NODE, MANDIBULAR	(48)	(48)	(48)	(46)	(45)
HISTIOCYTIC SARCOMA				2 (4%)	1 (2%)
LYMPHOMA; MALIGNANT	3 (6%)	1 (2%)		1 (2%)	1 (2%)
RHABDOMYOSARCOMA; METASTATIC		1 (2%)			
LYMPH NODE, MEDIASTINAL	(2)	(2)	(3)	(2)	(0)
HISTIOCYTIC SARCOMA			1 (33%)	1 (50%)	
LYMPHOMA; MALIGNANT			2 (67%)		
NEUROENDOCRINE CELL TUMOR; METASTATIC				1 (50%)	
LYMPH NODE, MESENTERIC	(48)	(50)	(48)	(49)	(48)
HEMANGIOMA			1 (2%)		

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
HISTIOCYTIC SARCOMA	1 (2%)		1 (2%)	3 (6%)	2 (4%)
LYMPHOMA; MALIGNANT	5 (10%)	2 (4%)	5 (10%)	1 (2%)	4 (8%)
NEUROENDOCRINE CELL TUMOR; METASTATIC				1 (2%)	
RHABDOMYOSARCOMA; METASTATIC		1 (2%)			
SPLEEN	(50)	(50)	(49)	(50)	(50)
HEMANGIOMA					1 (2%)
HEMANGIOSARCOMA		2 (4%)		1 (2%)	1 (2%)
HISTIOCYTIC SARCOMA	1 (2%)	1 (2%)	2 (4%)	3 (6%)	
LYMPHOMA; MALIGNANT	2 (4%)	2 (4%)	3 (6%)	1 (2%)	4 (8%)
THYMUS	(47)	(50)	(48)	(48)	(49)
ADENOCARCINOMA; METASTATIC				1 (2%)	
CHOLANGIOCARCINOMA; METASTATIC	1 (2%)				
HEMANGIOMA		1 (2%)			
HISTIOCYTIC SARCOMA				1 (2%)	1 (2%)
LYMPHOMA; MALIGNANT	3 (6%)	1 (2%)	3 (6%)	2 (4%)	1 (2%)
RHABDOMYOSARCOMA; METASTATIC		1 (2%)			
SCHWANNOMA; METASTATIC				1 (2%)	
THYMOMA; BENIGN	1 (2%)				
TUBULOESTROMAL CARCINOMA; METASTATIC	1 (2%)				

Study Number: C11054B-02

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sulfolane

CAS Number: 126-33-0

Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022

Time Report Requested: 11:17:46

Lab: Battelle with CRL

Female: Core Animals					
	Treatment Groups (mg/L)				
	0	30	100	300	1000
INTEGUMENTARY SYSTEM					
MAMMARY GLAND	(48)	(50)	(49)	(50)	(49)
ADENOCARCINOMA		1 (2%)			
SKIN	(50)	(50)	(50)	(50)	(49)
FIBROSARCOMA	3 (6%)				1 (2%)
HEMANGIOSARCOMA	1 (2%)		2 (4%)		
MELANOMA	1 (2%)				
PAPILLOMA, SQUAMOUS			1 (2%)		
SARCOMA		1 (2%)			
SCHWANNOMA; MALIGNANT		1 (2%)	1 (2%)		
SCHWANNOMA			1 (2%)	1 (2%)	
MUSCULOSKELETAL SYSTEM					
BONE	(1)	(2)	(1)	(0)	(1)
OSTEOSARCOMA		2 (100%)	1 (100%)		1 (100%)
BONE, FEMUR	(50)	(50)	(50)	(50)	(50)
SKELETAL MUSCLE	(1)	(2)	(1)	(3)	(1)
ADENOCARCINOMA; METASTATIC				1 (33%)	
RHABDOMYOSARCOMA	1 (100%)	2 (100%)	1 (100%)	2 (67%)	1 (100%)
NERVOUS SYSTEM					
BRAIN	(50)	(50)	(50)	(50)	(50)
NERVE, SCIATIC	(0)	(0)	(1)	(1)	(1)
NERVE, TRIGEMINAL	(0)	(0)	(1)	(1)	(1)
SPINAL CORD, CERVICAL	(0)	(0)	(1)	(1)	(1)
SPINAL CORD, LUMBAR	(0)	(0)	(1)	(1)	(1)
SPINAL CORD, THORACIC	(0)	(0)	(1)	(1)	(1)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
Treatment Groups (mg/L)					
	0	30	100	300	1000
RESPIRATORY SYSTEM					
LUNG	(50)	(50)	(50)	(50)	(50)
ADENOCARCINOMA; METASTATIC		1 (2%)		2 (4%)	
ALVEOLAR/BRONCHIOLAR ADENOMA; MULTIPLE					1 (2%)
ALVEOLAR/BRONCHIOLAR ADENOMA		2 (4%)	4 (8%)	5 (10%)	3 (6%)
ALVEOLAR/BRONCHIOLAR CARCINOMA	2 (4%)	2 (4%)	3 (6%)	1 (2%)	1 (2%)
CHOLANGIOCARCINOMA; METASTATIC	1 (2%)				
FIBROSARCOMA; METASTATIC	1 (2%)				
HEPATOBLASTOMA; METASTATIC					1 (2%)
HEPATOCELLULAR CARCINOMA; METASTATIC	1 (2%)	1 (2%)	2 (4%)	2 (4%)	2 (4%)
HEPATOCHOLANGIOCARCINOMA; METASTATIC			1 (2%)		
HISTIOCYTIC SARCOMA				1 (2%)	1 (2%)
LYMPHOMA; MALIGNANT	3 (6%)	2 (4%)	1 (2%)	1 (2%)	
OSTEOSARCOMA; METASTATIC		1 (2%)	1 (2%)		1 (2%)
RHABDOMYOSARCOMA; METASTATIC	1 (2%)	1 (2%)			
SCHWANNOMA; METASTATIC			1 (2%)	1 (2%)	
TUBULOSTROMAL CARCINOMA; METASTATIC	1 (2%)				
NOSE	(50)	(50)	(50)	(50)	(50)
TRACHEA	(49)	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM					
EAR	(0)	(0)	(0)	(1)	(0)
EYE	(48)	(50)	(50)	(49)	(50)
HARDERIAN GLAND	(50)	(50)	(49)	(50)	(49)
ADENOCARCINOMA		1 (2%)		1 (2%)	
ADENOMA	1 (2%)	2 (4%)	2 (4%)	5 (10%)	2 (4%)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Female: Core Animals					
Treatment Groups (mg/L)					
	0	30	100	300	1000
URINARY SYSTEM					
KIDNEY	(50)	(50)	(50)	(50)	(50)
HISTIOCYTIC SARCOMA			1 (2%)	1 (2%)	
LYMPHOMA; MALIGNANT	1 (2%)	2 (4%)	2 (4%)	1 (2%)	2 (4%)
OSTEOSARCOMA; METASTATIC					1 (2%)
URINARY BLADDER	(49)	(50)	(50)	(49)	(50)
LYMPHOMA; MALIGNANT	1 (2%)		1 (2%)		1 (2%)
SYSTEMIC LESIONS					
Multiple Organ(a)	(50)	(50)	(50)	(50)	(50)
HEMANGIOSARCOMA	1 (2%)	2 (4%)	3 (6%)	2 (4%)	3 (6%)
HISTIOCYTIC SARCOMA	2 (4%)	3 (6%)	2 (4%)	5 (10%)	3 (6%)
LYMPHOMA	5 (10%)	4 (8%)	6 (12%)	3 (6%)	5 (10%)

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

Tumor Summary Data for Female Core Animals	Treatment Groups (mg/L)				
	0	30	100	300	1000
Total Animals with Primary Neoplasms	0	0	0	0	0
Total Primary Neoplasms	0	0	0	0	0
Total Animals with Benign Neoplasms	25	20	22	24	23
Total Benign Neoplasms	60	50	50	60	58
Total Animals with Malignant Neoplasms	18	20	20	22	22
Total Malignant Neoplasms	118	96	132	128	104
Total Animals with Metastatic Neoplasms	6	5	6	6	4
Total Metastatic Neoplasms	28	20	18	24	14
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0

Study Number: C11054B-02
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sulfolane
CAS Number: 126-33-0
Target Version: Actions To Be Taken

Date Report Requested: 11/14/2022
Time Report Requested: 11:17:46
Lab: Battelle with CRL

LEGEND

Censored animals are animals not in one of the other disposition categories that are removed prior to the end of the study. The censored animals are included in the pathology data if microscopic examination of tissues was performed.

Number of animals examined given for each tissue.

Number of animals with observation reported with percent incidence in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

(a) - Number of animals with any tissue examined microscopically. Systemic lesions are included once in the total lesion count regardless of how many times they occurred in a single animal.

**** END OF REPORT ****